| Cladribin |
Cladribin passes into breast milk. |
Pregnancy, lactation |
– |
| Combination: paracetamol + codeine |
Sphincter of Oddi dysfunction |
Undesirable effects |
– |
| Dexketoprofen |
Fixed drug eruption |
Undesirable effects |
– |
| Isoniazid |
Severe drug-induced skin reactions (Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction (rash) with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP)): Inform patients of possible skin reactions and monitor for relevant symptoms; discontinue immediately when first symptoms appear; if confirmed, never use again |
Warnings and precautions, Undesirable effects |
– |
| Isoniazid |
Lupus-like syndrome |
Undesirable effects |
– |
| Leuprorelin |
Sudden cardiac death, QT prolongation, various arrhythmias, other cardiovascular diseases |
Warnings and precautions, Undesirable effects |
– |
| Leuprorelin |
Depression, suicidal tendencies |
Warnings and precautions, Undesirable effects |
– |
| Leuprorelin |
Transient ischaemic attack |
Undesirable effects |
– |
| Leuprorelin |
Dry skin, pigmentation disorders |
Undesirable effects |
– |
| Leuprorelin |
Anorexia |
Undesirable effects |
– |
| Leuprorelin |
Increased urinary frequency, urinary incontinence |
Undesirable effects |
– |
| Levetiracetam |
Risk of medication error with Keppra, 100 mg/mL oral solution, due to new delivery syringe |
Packs |
DHPC – Keppra® (Levetiracetam) |
| Lisdexamfetamine dimesylate |
Contraindication for patients with phaeochromocytoma |
Contraindications |
HPC – Lisdexamfetamindimesylat |
| Midazolam |
Kounis syndrome |
Undesirable effects |
– |
| Ocrelizumab |
Liver damage: Perform liver function tests before starting treatment and during treatment if symptoms occur; where liver damage is confirmed, discontinue ocrelizumab and only resume after symptoms have fully resolved and if another aetiology has been confirmed |
Warnings and precautions, Undesirable effects |
DHPC – Ocrevus® (Ocrelizumab) |
| Osimertinib+B21:E34 |
Hepatitis B reactivation: Monitoring of patients with positive HBV serology for clinically observed and laboratory-detected symptoms of reactivation |
Warnings and precautions, Undesirable effects |
– |
| Stimulants (dexamfetamine, dexmethylphenidate, lisdexamfetamine, methylphenidate) |
Increased intraocular pressure, glaucoma: If symptoms occur, contact doctor, stop therapy if necessary; ophthalmological monitoring where there is a history of increased intraocular pressure |
Warnings and precautions, Undesirable effects |
– |
| Stimulants (dexamfetamine, dexmethylphenidate, lisdexamfetamine, methylphenidate) |
Obsessive-compulsive disorder |
Undesirable effects |
– |
| Stimulants (dexamfetamine, dexmethylphenidate, lisdexamfetamine, methylphenidate) |
Dry eye |
Undesirable effects |
– |
| Teriflunomide |
There is an increased risk of haematological diseases in cases of preexisting blood count changes or restricted bone marrow function. If these occur, accelerated elimination procedures should be considered. |
Warnings and precautions |
– |
| Teriflunomide |
Caution is advised when switching between teriflunomide and other multiple sclerosis therapies due to potential additive immune effects. Washout periods must be observed depending on previous or subsequent therapy. |
Warnings and precautions |
– |
| Teriflunomide |
Falsely decreased ionised calcium levels may occur depending on the type of blood analyser. |
Warnings and precautions |
– |
| Teriflunomide |
Teriflunomide should be discontinued in women who wish to become pregnant and an accelerated elimination procedure is recommended. Before becoming pregnant, the teriflunomide plasma level must be measured twice at least 14 days apart and both values must be below 0.02 mg/L. |
Pregnancy, lactation |
– |
| Testosterone (topical) |
Instructions on avoiding accidental transfer to other people (particularly children) |
Dosage/use, Warnings and precautions |
– |
| Vancomycin |
Kounis syndrome: Cardiovascular symptoms due to allergic or hypersensitivity reactions with narrowing of the coronary arteries, can potentially result in myocardial infarction. |
Warnings and precautions, Undesirable effects |
– |
| Vancomycin |
Haemolytic anaemia |
Undesirable effects |
– |
| Vancomycin |
Alanine transferase elevated, aspartate aminotransferase elevated |
Undesirable effects |
– |
| Vasodilators (indication pulmonary hypertension) |
Pulmonary oedema in patients with pulmonary vein occlusion: If signs of pulmonary oedema occur, check for possibility of pulmonary vein occlusion; if confirmed, stop treatment |
Warnings and precautions |
– |
